Ser12
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser12  -  DRAK2 (mouse)

Site Information
RFDCRsVsGLLTTTP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1851300

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
B lymphocyte-spleen ( 1 ) , BaF3 ('B lymphocyte, precursor') ( 1 ) , HEK293T (epithelial) ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , splenocyte-spleen ( 1 ) , T lymphocyte-spleen ( 1 )

Upstream Regulation
Kinases, in vitro:
DRAK2 (mouse) ( 1 )
Treatments:
anti-CD3 ( 1 ) , anti-CD4 ( 1 ) , anti-IgM ( 1 ) , BAPTA-AM ( 1 ) , EGTA ( 1 ) , thapsigargin ( 1 )

Downstream Regulation
Effects of modification on DRAK2:
activity, induced ( 1 )

References 

1

Friedrich ML, et al. (2007) Modulation of DRAK2 autophosphorylation by antigen receptor signaling in primary lymphocytes. J Biol Chem 282, 4573-84
17182616   Curated Info